KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Travere Therapeutics (TVTX) Return on Capital Employed (2016 - 2025)

Historic Return on Capital Employed for Travere Therapeutics (TVTX) over the last 17 years, with Q3 2025 value amounting to 0.22%.

  • Travere Therapeutics' Return on Capital Employed rose 8400.0% to 0.22% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.22%, marking a year-over-year increase of 8400.0%. This contributed to the annual value of 0.66% for FY2024, which is 400.0% up from last year.
  • Per Travere Therapeutics' latest filing, its Return on Capital Employed stood at 0.22% for Q3 2025, which was up 8400.0% from 0.48% recorded in Q2 2025.
  • In the past 5 years, Travere Therapeutics' Return on Capital Employed registered a high of 0.22% during Q3 2025, and its lowest value of 1.06% during Q3 2024.
  • Its 5-year average for Return on Capital Employed is 0.55%, with a median of 0.57% in 2023.
  • Its Return on Capital Employed has fluctuated over the past 5 years, first tumbled by -4700bps in 2024, then surged by 8400bps in 2025.
  • Over the past 5 years, Travere Therapeutics' Return on Capital Employed (Quarter) stood at 0.31% in 2021, then tumbled by -88bps to 0.57% in 2022, then dropped by -7bps to 0.61% in 2023, then crashed by -52bps to 0.93% in 2024, then soared by 76bps to 0.22% in 2025.
  • Its Return on Capital Employed was 0.22% in Q3 2025, compared to 0.48% in Q2 2025 and 0.58% in Q1 2025.